Trogenix reported a $95 million Series A funding round aimed at bolstering its novel 'Trojan horse' therapeutic platform targeting glioblastoma, a highly aggressive form of brain cancer. This financing supports the company’s progression towards clinical trials, reflecting growing investment in innovative approaches to overcome central nervous system drug delivery challenges.